ロード中...
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
BACKGROUND: Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims...
保存先:
| 出版年: | Chin Med J (Engl) |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7147283/ https://ncbi.nlm.nih.gov/pubmed/32149769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000797 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|